acute panmyelosis with myelofibrosis
Jump to navigation
Jump to search
Introduction
poorly defined disorder
Etiology
- clonal disorder
- toxic exposure to the bone marrow
Epidemiology
- rare
- mostly adults
Microscopic pathology
- proliferative process involves all major myeloid lines: erythroid, granulocytic, megakaryocytic
- abnormal megakaryocytes
- macrocytic erythropoiesis
- defects in neutrophil production
- myelofibrosis
Immunophenotype
- phenotypic heterogeneity
- one or more myeloid antigens: CD13, CD33, CD117, myeloperoxidase
Genetics
- complex abnormalities
- frequent involvement of chromosomes 5 and/or 7
Clinical manifestations
- weakness
- fatigue
- marked pancytopenia
- no or minimal splenomegaly
- rapidly progressive course
Laboratory
- bone marrow biopsy
- complete blood count
- pancytopenia
- very few blasts
- flow cytometry
- CD34-positive leukocytes
Differential diagnosis
- AML with multilineage dysplasia
- acute megakaryoblastic leukemia
- other types of acute leukemia with marrow fibrosis
- metastatic neoplasm with desmoplasia
- chronic idiopathic myelofibrosis
Management
- stem cell transplantation has been used
- prognosis: median survival: 8 months
Notes
- currently classified as a form of acute myeloid leukemia (AML)
- lack of blasts in the peripheral blood would seem to preclude AML
- classification as a form of myelodysplastic syndrome seems more appropriate
More general terms
References
- ↑ Wikipedia: Acute panmyelosis with myelofibrosis http://en.wikipedia.org/wiki/Acute_panmyelosis_with_myelofibrosis
- ↑ WHO Classification Tumours of Haematopoietic and Lymphoid Tissues. IARC Press 2001
- ↑ Bae E, Park CJ, Cho YU et al Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. Int J Lab Hematol. 2013 Dec;35(6):629-36. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23693053